Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | METAP2 | P50579 | 2/20 | 0.59 |
| ▸ | METAP1 | P53582 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | COMT | P21964 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27032828 | 0.98 | MMP2 (0.57) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL4063648 | 0.79 | MMP2 (0.63) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL1286608 | 0.79 | MMP2 (0.63) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL28068062 | 0.79 | TSHR (0.53) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL9379959 | 0.78 | MMP2 (0.61) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL115436 | 0.76 | KDM4E (0.59) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL5540587 | 0.76 | MMP2 (0.59) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL6142549 | 0.76 | LMNA (0.58) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL20480582 | 0.76 | MMP2 (0.59) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL31716531 | 0.76 | LMNA (0.58) | MMP2TSHRMETAP2METAP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055534-A1 | COMBINATORIAL PHOTO-CONTROLLED SPATIAL SEQUENCING AND LABELING | UNIV WASHINGTON (US) | 2026-02-26 | — | — | US | disclosed |
| US-12492491-B2 | Combinatorial photo-controlled spatial sequencing and labeling | UNIVERSITY OF WASHINGTON (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250288703-A1 | Alpha Emitter Compositions And Methods | NANT HOLDINGS IP LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250129049-A1 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-24 | — | — | US | disclosed |
| US-12194111-B2 | Alpha emitter compositions and methods | NANT HOLDINGS IP, LLC (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4455134-A1 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | Sumitomo Pharma Co., Ltd. (JP) | 2024-10-30 | — | — | EP | disclosed |
| CN-118434726-A | 1H-pyrazol-3-amine derivatives having a bicyclic skeleton | 住友制药株式会社 | 2024-08-02 | — | — | CN | disclosed |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| WO-2023120696-A1 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | 住友ファーマ株式会社 | 2023-06-29 | — | — | WO | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | disclosed |
| US-20100022761-A1 | PHOTOCLEAVABLE LINKER METHODS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-28 | — | — | US | disclosed |
| US-20100022761-A1 | PHOTOCLEAVABLE LINKER METHODS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-28 | — | — | US | disclosed |
| US-20080255498-A1 | Sensitizer Solutions, Systems, and Methods of Use | OROSCIENCE, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1933941-A2 | TREATMENT SYSTEMS FOR DELIVERY OF SENSITIZER SOLUTIONS | Houle, Philip R. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7304168-B2 | Photo-caged fluorescent molecules | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2007025244-A2 | TREATMENT SYSTEMS FOR DELIVERY OF SENSITIZER SOLUTIONS | HOULE PHILIP R (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20050042662-A1 | Photo-caged fluorescent molecules | BOARD OF REGENTS (US) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288703-A1 | Alpha Emitter Compositions And Methods | PSMA2, TPSG1, FAP | MMP2 448/4885TSHR 1188/4885METAP2 469/4885 |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | MMP2 4734/4885TSHR 4785/4885METAP2 2545/4885 |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NUDT1, RECQL, PNP | MMP2 2786/4885TSHR 4727/4885METAP2 703/4885 |
| US-12194111-B2 | Alpha emitter compositions and methods | PSMA2, TPSG1, FAP | MMP2 448/4885TSHR 1188/4885METAP2 469/4885 |
| US-20100022761-A1 | PHOTOCLEAVABLE LINKER METHODS AND COMPOSITIONS | NSUN2, RNGTT, METTL16 | MMP2 3012/4885TSHR 4560/4885METAP2 1472/4885 |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, PMP22 | MMP2 4734/4885TSHR 4785/4885METAP2 2545/4885 |
| US-20250129049-A1 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | CHEK1, BUB1B, CHEK2 | MMP2 4389/4885TSHR 3103/4885METAP2 4401/4885 |
| US-20050042662-A1 | Photo-caged fluorescent molecules | GJA1, GJB2, CBX7 | MMP2 2603/4885TSHR 4760/4885METAP2 3751/4885 |
| US-20260055534-A1 | COMBINATORIAL PHOTO-CONTROLLED SPATIAL SEQUENCING AND LABELING | PHAX, POLL, PCNA | MMP2 4404/4885TSHR 3210/4885METAP2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.